Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1

Conditions

Lymphoma, Non-Hodgkin 4Leukemia, Myeloid, Acute 4Leukemia 4Colonic Neoplasms 4Congenital Abnormalities 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Somatostatinoma 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Myeloproliferative Disorders 2Multiple Myeloma 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma 2Lung Neoplasms 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Colorectal Neoplasms 2Carcinoma, Islet Cell 2Vulvar Neoplasms 1Vipoma 1Vaginal Neoplasms 1

Interventions

lanreotide 1antineoplaston AS 2-1 1antineoplaston A10 1Temozolomide 1Surveys and Questionnaires 1Solutions 1Radiosurgery 1Observation 1Microarray Analysis 1Injections 1Early Intervention, Educational 1Diet, Mediterranean 1Diet, Ketogenic 1DNA Methylation 1Complementary Therapies 1Biological Therapy 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Growth Hormone-Secreting Pituitary Adenoma × Biological Therapy × Clear all
NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡